Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
NRx Pharmaceuticals, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
NRXP
Nasdaq
2830
www.nrxpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025
- Feb 6th, 2025 1:03 pm
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor
- Feb 3rd, 2025 1:59 pm
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition
- Jan 28th, 2025 1:05 pm
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt
- Jan 28th, 2025 1:03 pm
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement
- Jan 21st, 2025 1:02 pm
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel
- Jan 14th, 2025 1:03 pm
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market
- Jan 13th, 2025 1:04 pm
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Conduct Investor Workshop at the Mar-A-Lago Club
- Jan 10th, 2025 1:04 pm
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San Francisco
- Jan 7th, 2025 1:07 pm
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations
- Jan 6th, 2025 3:16 pm
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dura Medical as the Expected Initial Florida Acquisition for its Planned International Network of Interventional Psychiatry Clinics
- Jan 6th, 2025 1:03 pm
HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Subsidiary, Will Host an Investor Workshop for Qualified Institutional Investors at the Mar-A-Lago Club During the Week of January 6, 2025
- Jan 3rd, 2025 1:03 pm
Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics
- Jan 2nd, 2025 1:03 pm
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression
- Dec 30th, 2024 1:03 pm
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024
- Nov 26th, 2024 1:03 pm
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials"
- Nov 25th, 2024 1:03 pm
NRX Pharmaceuticals Inc (NRXP) Q3 2024 Earnings Call Highlights: Significant Reduction in ...
- Nov 19th, 2024 7:03 am
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer
- Nov 18th, 2024 9:05 pm
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update
- Nov 14th, 2024 9:05 pm
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024
- Nov 13th, 2024 1:03 pm
Scroll